-
BioPharma Dive – AI / Data3 months agoPfizer, Valneva to seek approval of Lyme disease vaccine despite mixed study results
The partners said the shot produced “clinically meaningful” efficacy despite missing its main study objective, a finding they blamed on a lower-than-expected rate of infections during...
-
Biotech Industry Intelligence3 months ago
WuXi AppTec’s bet on the US pays off as revenues dip elsewhere
WuXi AppTec’s bet on the US pays off as revenues dip elsewhere
-
Biotech Industry Intelligence3 months ago
Former Acorda CEO Ron Cohen emerges at Parkinson’s cell therapy biotech Oryon
Former Acorda CEO Ron Cohen emerges at Parkinson’s cell therapy biotech Oryon
-
Uncategorized3 months agoRoche leads AI drug discovery with new NVIDIA deal
Roche now operates the pharmaceutical industry’s largest announced hybrid-cloud AI factory, totalling more than 3,500 GPUs, following an expansion of its global AI infrastructure. The company...
-
AI & Machine Learning in Biotechnology3 months agoSTAT+: Epic says it has uncovered rot in patient record sharing. Will HHS act?
In a recent court filing, electronic health records giant Epic Systems proved one of health care providers’ worst fears: Companies are posing as providers to gain...
-
Fierce Biotech3 months ago
MRI providers keep eye on rising helium prices amid war in Iran
Qatar’s exports of natural gas and helium—the latter essential for MRI scans—were effectively halted after Iran closed the Strait of Hormuz and attacked one of the...
-
BioPharma Dive – AI / Data3 months agoFDA seeks feedback on voucher program; Study data lift ‘overhang’ on Insmed shares
Industry executives can share their views on the “national priority” program at a June meeting. Elsewhere, Sanofi licensed a T cell engager and Acorda’s former CEO...
-
Endpoints News3 months ago
CEO and C-suite are out in battle for control of Aurinia
Biotech takeover specialist Kevin Tang is consolidating control at Aurinia Pharmaceuticals, and has replaced the CEO and C-suite at the company, according to a securities filing...
-
Endpoints News3 months ago
Dizal’s first-line lung cancer data; Sanofi expands in China
Plus, news about Opdivo: 📊 Dizal drug succeeds in Phase 3 lung cancer study: The drug Zegfrovy improved progression-free survival compared to chemo in first-line non-small...
-
Fierce Biotech3 months ago
Merck hands over $20M in IBD drug target deal with Flagship’s Quotient
Looking to devise new drug targets for inflammatory bowel disease, Merck will pay Flagship Pioneering’s Quotient Therapeutics $20 million upfront for access to the biotech’s somatic...
Laser‑Driven Phase Contrast Enhances Cryo‑EM Resolution of Small Proteins
STAT+: Updated: Tracking RFK Jr.’s promises to remake health in America
